uniQure N.V. QURE

NAS: QURE | ISIN: NL0010696654   30/04/2025
14,76 USD (+6,49%)
(+6,49%)   30/04/2025

17 april 2025 · uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease · Persbericht

27 februari 2025 · uniQure Announces 2024 Financial Results and Highlights Recent Company Progress · Persbericht

3 februari 2025 · uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease · Persbericht

30 januari 2025 · uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS · Persbericht

8 januari 2025 · uniQure Announces Pricing of its Public Offering · Persbericht

7 januari 2025 · uniQure Announces Proposed Public Offering · Persbericht

10 december 2024 · uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease · Persbericht

21 november 2024 · uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy · Persbericht

5 november 2024 · uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress · Persbericht

15 oktober 2024 · uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS · Persbericht

23 september 2024 · uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease · Persbericht

15 augustus 2024 · uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease · Persbericht

1 augustus 2024 · uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update · Persbericht

23 juli 2024 · uniQure Announces Closing of Sale of Manufacturing Facility to Genezen · Persbericht

9 juli 2024 · uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease · Persbericht

1 juli 2024 · uniQure Announces Sale of Commercial Manufacturing Facility to Genezen · Persbericht

1 juli 2024 · Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA · Persbericht

3 juni 2024 · uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease · Persbericht

7 mei 2024 · uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress · Persbericht

28 februari 2024 · uniQure Announces 2023 Financial Results and Highlights Recent Company Progress · Persbericht

Mijn selecties